RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Emerging roles of non-coding RNA derived from extracellular vesicles in regulating PD-1/PD-L1 pathway: insights into cancer immunotherapy and clinical applications.
Emerging roles of non-coding RNA derived from extracellular vesicles in regulating PD-1/PD-L1 pathway: insights into cancer immunotherapy and clinical applications.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
大量研究表明,细胞外囊泡(EVs)携带多种非编码RNA(ncRNAs),这些ncRNAs可被邻近细胞摄取或通过体液运输至远处部位,从而促进细胞间通讯并调控多种细胞功能。在肿瘤微环境中,EV-ncRNA一方面调控PD-L1的表达,从而影响肿瘤免疫逃逸,促进肿瘤细胞增殖,并增强体内肿瘤生长、侵袭和转移。另一方面,这些特定的EV-ncRNAs还可通过多种分子机制调节免疫细胞(如CD8+ T细胞、巨噬细胞和NK细胞)的功能,诱导免疫抑制微环境并促进对抗PD-1治疗的耐药。
因此,深入探究EV-ncRNA调控免疫检查点的分子机制,为选择性靶向EV-ncRNAs的策略提供了令人期待的治疗前景。在本综述中,我们详细阐述了EV-ncRNAs在癌症背景下的前沿研究进展,并剖析其在PD-1/PD-L1免疫检查点通路中的关键作用。
我们还重点介绍了EV-ncRNAs在抗PD-1/PD-L1免疫治疗中有前景的临床应用,将基础研究与实际临床应用相衔接。
Numerous studies have demonstrated that extracellular vesicles (EVs) carry a variety of noncoding RNAs (ncRNAs), which can be taken up by neighboring cells or transported to distant sites via bodily fluids, thereby facilitating intercellular communication and regulating multiple cellular functions.
Within the tumor microenvironment, EV-ncRNA, on the one hand, regulate the expression of PD-L1, thereby influencing tumor immune evasion, promoting tumor cell proliferation, and enhancing tumor growth, invasion, and metastasis in vivo. On the other hand, these specific EV-ncRNAs can also modulate the functions of immune cells (such as CD8 + T cells, macrophages, and NK cells) through various molecular mechanisms, inducing an immunosuppressive microenvironment and promoting resistance to anti-PD-1 therapy.
Therefore, delving into the molecular mechanisms underlying EV-ncRNA regulation of immune checkpoints presents compelling therapeutic prospects for strategies that selectively target EV-ncRNAs. In this review, we elaborate on the cutting-edge research progress related to EV-ncRNAs in the context of cancer and dissect their pivotal roles in the PD-1/PD-L1 immune checkpoint pathway.
We also highlight the promising clinical applications of EV-ncRNAs in anti-PD-1/PD-L1 immunotherapy, bridging basic research with practical clinical applications.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。